Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
BoD
Hans-Joachim Lohrisch - Director
-
Dr. Lohrisch was CEO of Altana Pharma AG from 1999 to 2006 and a member of the Board of Management of ALTANA AG, a DAX 30 company, from 1999 to 2006. In the course of the spin-out and take-over of Altana Pharma by Nycomed, he joined the Board of Nycomed SA, a position that he continues to hold. Prior to Altana, Dr. Lohrisch was at Merck KGaA for 21 years in Germany, the UK and Portugal in various management positions including R&D project management, licensing, strategic marketing and general management with international group responsibilities. Dr. Lohrisch’s career in the pharmaceutical industry spans a total of 30 years. He holds a doctorate in Organic Chemistry from Bonn University. Dr Lohrisch joined Newron Board of Directors on 14th January 2008.